Table 3

Studies on post-infectious functional gastrointestinal disorders (FGID) after viral infections

StudyPatients/controls (n)PathogenFrequency of FGIDs among casesFrequency of FGIDs among controlsFollow-up (months)
Marshall et al (2007)41 89/29NorovirusIBS: 23.6%IBS: 3.4%3
Zanini et al (2012)42 186/198NorovirusIBS: 21.5%IBS: 1.5%12
Saps et al (2009)43 44/44RotavirusFGIDs: 16%)FGIDs: 3/44 (7%)24–48
Ghoshal et al (2021)45 280/264SARS- CoV-2IBS: 5.3%
UD: 2.1%
IBS-UD overlap: 1.8%
IBS: 0.3%6
Velez et al (2021)46 200 /no controlsSARS-CoV-2IBS: 29%
FD: 1%
Overlap: 9.5%
6
JW Blackett et al (2022)47 749 /no controlsSARS-CoV-29.6%—diarrhoea
11%—constipation
9.4%—abdomen pain
7.1%—nausea/vomiting 16%—heartburn
6
Oshima et al (2021)50 5157 /no controlsSARS-CoV-2FD: 8.5%
IBS: 16.6%
FD-IBS overlap: 4.0%
6
Nakov et al (2022)51 1896/980SARS-CoV-2IBS (26.3% vs 20.0%) Functional dyspepsia (18.3% vs 12.7%), Heartburn (31.7% vs 26.2%)
Self-reported milk intolerance (43.5% vs 37.8%)
6
Noviello et al (2021)52 164/183SARS-CoV-2Adjusted RRs for loose stools and somatisation were increased after infection: 1.88 (0.99–3.54) and 3.62 (1.01–6.23)5
  • FD, Functional dyspepsia; IBS, Irritable bowel syndrome; UD, Uninvestigated dyspepsia.